2023
DOI: 10.1097/hep.0000000000000426
|View full text |Cite
|
Sign up to set email alerts
|

Telomere dysfunction in chronic liver disease: The link from aging

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 150 publications
0
3
0
Order By: Relevance
“…The loss of TRMs in these specified niches is likely to predispose the tissue to increased infiltrates, fibrosis and pathogen susceptibility 36,51,52,72,73 . Moreover, the loss of interaction with stellate cells in STING -/livers may have another outcome, liver fibrosis is a common feature of aging livers and considered pathological 72,[74][75][76][77][78] . However, fibrosis may have the inadvertent benefit of maintaining structural integrity of the tissue architecture.…”
Section: Discussionmentioning
confidence: 99%
“…The loss of TRMs in these specified niches is likely to predispose the tissue to increased infiltrates, fibrosis and pathogen susceptibility 36,51,52,72,73 . Moreover, the loss of interaction with stellate cells in STING -/livers may have another outcome, liver fibrosis is a common feature of aging livers and considered pathological 72,[74][75][76][77][78] . However, fibrosis may have the inadvertent benefit of maintaining structural integrity of the tissue architecture.…”
Section: Discussionmentioning
confidence: 99%
“…Meanwhile, testing for TBD, either through Flow-FISH or genetic screening, in patients with unexplained liver abnormalities may become a standard practice which will help identify those at risk of TBD. [6] Furthermore, recognition of known TRG mutations will allow for appropriate screening in first-degree relatives, as indicated.…”
mentioning
confidence: 99%
“…This study, among others, suggests that androgen therapy may be a promising avenue for addressing telomere shortening in patients with TBD, but whether they significantly change the course of liver disease remains to be seen. Meanwhile, testing for TBD, either through Flow-FISH or genetic screening, in patients with unexplained liver abnormalities may become a standard practice which will help identify those at risk of TBD 6 . Furthermore, recognition of known TRG mutations will allow for appropriate screening in first-degree relatives, as indicated.…”
mentioning
confidence: 99%